Resveratrol (3,5,4’-Trihydroxystilbene) and its properties in oral diseases (Review)

Experimental and Therapeutic Medicine

Volumn 14, Issue 1, 2017, Pages 3-9

  Perrone, Donatella ^a   Fuggetta, Maria Pia ^b   Ardito, Fatima ^a   Cottarelli, Andrea ^b   de Filippis, Anna ^c   Ravagnan, Giampietro ^d   de Maria, Salvatore ^d   Lo Muzio, Lorenzo ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

^b INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d Glures srl Operative Unit Biochemical and Biophysical Department   (Italy)

Author keywords

Chemoprevention; Oral disease; Oral squamous cell carcinoma; Oxidative stress; Resveratrol

Indexed keywords

ANTIOXIDANT; CASPASE 3; DOXORUBICIN; GLUCOSIDE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; LOW DENSITY LIPOPROTEIN; REACTIVE OXYGEN METABOLITE; RESVERATROL; TRANSCRIPTION FACTOR ZEB1;

ABSENCE OF SIDE EFFECTS; ANTIOXIDANT ACTIVITY; APOPTOSIS; ATTENTION; BIOCHEMISTRY; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CHEMOPROPHYLAXIS; DNA DAMAGE; DNA FRAGMENTATION; DOWN REGULATION; DRUG ADSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG SOLUBILITY; DRUG SYNTHESIS; G2 PHASE CELL CYCLE CHECKPOINT; GROWTH INHIBITION; HEALTH PROMOTION; LIFESTYLE MODIFICATION; LIPID PEROXIDATION; MOUTH DISEASE; MOUTH SQUAMOUS CELL CARCINOMA; NEUROPROTECTION; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; QUALITY OF LIFE; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 85020526562     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2017.4472     Document Type: Review

References (125)

1. Petersen PE: Oral cancer prevention and control-the approach of the World Health Organization. Oral Oncol 45: 454-460, 2009.
2. Petersen PE: World Health Organization global policy for improvement of oral health-World Health Assembly 2007. Int Dent J 58: 115-121, 2008.
3. Marthaler TM and Petersen PE: Salt fluoridation-an alternative in automatic prevention of dental caries. Int Dent J 55: 351-358, 2005.
4. Petersen PE: Tobacco and oral health-the role of the World Health Organization. Oral Health Prev Dent 1: 309-315, 2003.
5. Petersen PE, Bourgeois D, Bratthall D and Ogawa H: Oral health information systems-towards measuring progress in oral health promotion and disease prevention. Bull World Health Organ, 83,: 686-693, 2005.
6. Moynihan P and Petersen PE: Diet, nutrition and the prevention of dental diseases. Public Health Nutr 7: 201-226, 2004.
7. Moynihan PJ: The role of diet and nutrition in the etiology and prevention of oral diseases. Bull World Health Organ 83: 694-699, 2005.
8. Oral Health Worldwide: A report by FDI World Dental Federation. FDI World Dental Federation, Geneva, 2014.
9. Nagpal M and Sood S: Role of curcumin in systemic and oral health: An overview. J Nat Sci Biol Med 4: 3-7, 2013.
10. Elattar TM and Virji AS: The inhibitory effect of curcumin, genistein, quercetin and cisplatin on the growth of oral cancer cells in vitro. Anticancer Res 20: 1733-1738, 2000.
11. Ramshankar V and Krishnamurthy A: Chemoprevention of oral cancer: Green tea experience. J Nat Sci Biol Med 5: 3-7, 2014.
12. Duan J, Yue W, E J, Malhotra J, Lu SE, Gu J, Xu F and Tan XL: In vitro comparative studies of resveratrol and triacetylresveratrol on cell proliferation, apoptosis, and STAT3 and NFκB signaling in pancreatic cancer cells. Sci Rep 6: 31672, 2016.
13. Tao W, Xu X, Wang X, Li B, Wang Y, Li Y and Yang L: Network pharmacology-based prediction of the active ingredients and potential targets of Chinese herbal Radix Curcumae formula for application to cardiovascular disease. J Ethnopharmacol 145: 1-10, 2013.
14. Jiang M, Lu C, Chen G, Xiao C, Zha Q, Niu X, Chen S and Lu A: Understanding the molecular mechanism of interventions in treating rheumatoid arthritis patients with corresponding traditional Chinese medicine patterns based on bioinformatics approach. Evid Based Complement Alternat Med 2012: 129452, 2012.
15. Li S and Zhang B: Traditional Chinese medicine network pharmacology: Theory, methodology and application. Chin J Nat Med 11: 110-120, 2013.
16. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S and Takada Y: Role of resveratrol in prevention and therapy of cancer: Preclinical and clinical studies. Anticancer Res 24: 2783-2840, 2004.
17. Pervaiz S and Holme AL: Resveratrol: Its biologic targets and functional activity. Antioxid Redox Signal 11: 2851-2897, 2009.
18. Harikumar KB and Aggarwal BB: Resveratrol: A multitargeted agent for age-associated chronic diseases. Cell Cycle 7: 1020-1035, 2008.
19. Athar M, Back JH, Kopelovich L, Bickers DR and Kim AL: Multiple molecular targets of resveratrol: Anti-carcinogenic mechanisms. Arch Biochem Biophys 486: 95-102, 2009.
20. Kerem Z, Chetrit D, Shoseyov O and Regev Shoshani G: Protection of lipids from oxidation by epicatechin, trans-resveratrol, and gallic and caffeic acids in intestinal model systems. J Agric Food Chem 54: 10288-10293, 2006.
21. Murias M, Handler N, Erker T, Pleban K, Ecker G, Saiko P, Szekeres T and Jäger W: Resveratrol analogues as selective cyclooxygenase-2 inhibitors: Synthesis and structure-activity relationship. Bioorg Med Chem 12: 5571-5578, 2004.
22. Gehm BD, McAndrews JM, Chien PY and Jameson JL: Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci USA 94: 14138-14143, 1997.
23. Kraft TE, Parisotto D, Schempp C and Efferth T: Fighting cancer with red wine? Molecular mechanisms of resveratrol. Crit Rev Food Sci Nutr 49: 782-799, 2009.
24. Benová B, Adam M, Onderková K, Královsky J and Krajicek M: Analysis of selected stilbenes in Polygonum cuspidatum by HPLC coupled with CoulArray detection. J Sep Sci 31: 2404-2409, 2008.
25. Wu JM, Wang ZR, Hsieh TC, Bruder JL, Zou JG and Huang YZ: Mechanism of cardioprotection by resveratrol, a phenolic antioxidant present in red wine (Review). Int J Mol Med 8: 3-17, 2001.
26. Jung JC, Lim E, Lee Y, Kang JM, Kim H, Jang S, Oh S and Jung M: Synthesis of novel trans-stilbene derivatives and evaluation of their potent antioxidant and neuroprotective effects. Eur J Med Chem 44: 3166-3174, 2009.
27. King RE, Kent KD and Bomser JA: Resveratrol reduces oxidation and proliferation of human retinal pigment epithelial cells via extracellular signal-regulated kinase inhibition. Chem Biol Interact 151: 143-149, 2005.
28. Saiko P, Szakmary A, Jaeger W and Szekeres T: Resveratrol and its analogs: Defense against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutat Res 658: 68-94, 2008.
29. Szekeres T, Fritzer Szekeres M, Saiko P and Jäger W: Resveratrol and resveratrol analogues-structure-activity relationship. Pharm Res 27: 1042-1048, 2010.
30. Szekeres T, Saiko P, Fritzer-Szekeres M, Djavan B and Jäger W: Chemopreventive effects of resveratrol and resveratrol derivatives. Ann N Y Acad Sci 1215: 89-95, 2011.
31. Piotrowska H, Kucinska M and Murias M: Biological activity of piceatannol: Leaving the shadow of resveratrol. Mutat Res 750: 60-82, 2012.
32. Petrovski G, Gurusamy N and Das DK: Resveratrol in cardiovascular health and disease. Ann N Y Acad Sci 1215: 22-33, 2011.
33. Ndiaye M, Philippe C, Mukhtar H and Ahmad N: The grape antioxidant resveratrol for skin disorders: Promise, prospects, and challenges. Arch Biochem Biophys 508: 164-170, 2011.
34. Szkudelska K and Szkudelski T: Resveratrol, obesity and diabetes. Eur J Pharmacol 635: 1-8, 2010.
35. Wahba MG, Messiha BA and Abo-Saif AA: Protective effects of fenofibrate and resveratrol in an aggressive model of rheumatoid arthritis in rats. Pharm Biol 54: 1705-1715, 2016.
36. Bastianetto S, Ménard C and Quirion R: Neuroprotective action of resveratrol. Biochim Biophys Acta 1852: 1195-1201, 2015.
37. Markus MA and Morris BJ: Resveratrol in prevention and treatment of common clinical conditions of aging. Clin Interv Aging 3: 331-339, 2008.
38. Frémont L: Biological effects of resveratrol. Life Sci 66: 663-673, 2000.
39. Wang W, Tang K, Yang HR, Wen PF, Zhang P, Wang HL and Huang WD: Distribution of resveratrol and stilbene synthase in young grape plants (Vitis vinifera L. cv. Cabernet Sauvignon) and the effect of UV-C on its accumulation. Plant Physiol Biochem 48: 142-152, 2010.
40. Soleas GJ, Diamandis EP and Goldberg DM: Resveratrol: A molecule whose time has come? And gone? Clin Biochem 30: 91-113, 1997.
41. Vastano BC, Chen Y, Zhu N, Ho CT, Zhou Z and Rosen RT: Isolation and identification of stilbenes in two varieties of Polygonum cuspidatum. J Agric Food Chem 48: 253-256, 2000.
42. Hathway DE and Seakins JW: Hydroxystilbenes of Eucalyptus wandoo. Biochem J 72: 369-374, 1959.
43. Rolfs CH and Kindl H: Stilbene synthase and chalcone synthase: Two different constitutive enzymes in cultured cells of Picea excelsa. Plant Physiol 75: 489-492, 1984.
44. King RE, Bomser JA and Min DB: Bioactivity of resveratrol. Comprehensive Reviews in Food Science and Food Safety 5: 65-70, 2006.
45. Takaoka MJ: The phenolic substances of white hellebore (Veratrum grandiflorum Loes. fil.). J Faculty Sci 3: 1-16, 1940.
46. Baur JA and Sinclair DA: Therapeutic potential of resveratrol: The in vivo evidence. Nat Rev Drug Discov 5: 493-506, 2006.
47. Langcake P and Pryce RJ: A new class of phytoalexins from grapevines. Experientia 33: 151-152, 1977.
48. Renaud S and de Lorgeril M: Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 339: 1523-1526, 1992.
49. Counet C, Callemien D and Collin S: Chocolate and cocoa: New sources of trans-resveratrol and trans-piceid. Food Chemistry 98: 649-657, 2006.
50. Wang Y, Catana F, Yang Y, Roderick R and van Breemen RB: An LC-MS method for analyzing total resveratrol in grape juice, cranberry juice, and in wine. J Agric Food Chem 50: 431-435, 2002.
51. Siemann EH and Creasy LL: Concentration of the Phytoalexin resveratrol in wine. Am J Enol Vitic 43: 49-52, 1992.
52. Guerrero RF, Garcia-Parrilla MC, Puertas B and Cantos Villar E: Wine, resveratrol and health: A review. Nat Prod Commun 4: 635-658, 2009.
53. Stervbo U, Vang O and Bonnesen C: A review of the content of the putative chemopreventive phytoalexin resveratrol in red wine. Food Chemistry 101: 449-457, 2007.
54. Figueiras TS, Neves-Petersen MT and Petersen SB: Activation energy of light induced isomerization of resveratrol. J Fluoresc 21: 1897-1906, 2011.
55. Cai YJ, Wei QY, Fang JG, Yang L, Liu ZL, Wyche JH and Han Z: The 3,4-dihydroxyl groups are important for trans-resveratrol analogs to exhibit enhanced antioxidant and apoptotic activities. Anticancer Res 24: 999-1002, 2004.
56. Wieder T, Prokop A, Bagci B, Essmann F, Bernicke D, Schulze Osthoff K, Dörken B, Schmalz HG, Daniel PT and Henze G: Piceatannol, a hydroxylated analog of the chemopreventive agent resveratrol, is a potent inducer of apoptosis in the lymphoma cell line BJAB and in primary, leukemic lymphoblasts. Leukemia 15: 1735-1742, 2001.
57. Yang T, Wang L, Zhu M, Zhang L and Yan L: Properties and molecular mechanisms of resveratrol: A review. Pharmazie 70: 501-506, 2015.
58. Biasutto L, Marotta E, Bradaschia A, Fallica M, Mattarei A, Garbisa S, Zoratti M and Paradisi C: Soluble polyphenols: Synthesis and bioavailability of 3,4’,5-tri(alpha-D-glucose-3-O-succinyl) resveratrol. Bioorg Med Chem Lett 19: 6721-6724, 2009.
59. Ratnam DV, Ankola DD, Bhardwaj V, Sahana DK and Kumar MN: Role of antioxidants in prophylaxis and therapy: A pharmaceutical perspective. J Control Release 113: 189-207, 2006.
60. Lin YL, Chang HC, Chen TL, Chang JH, Chiu WT, Lin JW and Chen RM: Resveratrol protects against oxidized LDL-induced breakage of the blood-brain barrier by lessening disruption of tight junctions and apoptotic insults to mouse cerebrovascular endothelial cells. J Nutr 140: 2187-2192, 2010.
61. Du QH, Peng C and Zhang H: Polydatin: A review of pharmacology and pharmacokinetics. Pharm Biol 51: 1347-1354, 2013.
62. Plou FJ, Segura AGd and Ballesteros A: Application of Glycosidases and Transglycosidases in the synthesis of oligosaccharides. In: Industrial enzymes: Structure, function and applications. Polaina J and MacCabe AP (eds.) Springer Netherlands, Dordrecht, pp 141-157, 2007.
63. Bertrand A, Morel S, Lefoulon F, Rolland Y, Monsan P and Remaud Simeon M: Leuconostoc mesenteroides glucansucrase synthesis of flavonoid glucosides by acceptor reactions in aqueous-organic solvents. Carbohydr Res 341: 855-863, 2006.
64. Cichewicz RH and Kouzi SA: Biotransformation of resveratrol to piceid by Bacillus cereus. J Nat Prod 61: 1313-1314, 1998.
65. Baek SJ, Wilson LC and Eling TE: Resveratrol enhances the expression of non-steroidal anti-inflammatory drug-activated gene (NAG-1) by increasing the expression of p53. Carcinogenesis 23: 425-434, 2002.
66. Aziz MH, Kumar R and Ahmad N: Cancer chemoprevention by resveratrol: In vitro and in vivo studies and the underlying mechanisms (review). Int J Oncol 23: 17-28, 2003.
67. Walle T, Hsieh F, DeLegge MH, Oatis JE Jr and Walle UK: High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 32: 1377-1382, 2004.
68. Marier JF, Vachon P, Gritsas A, Zhang J, Moreau JP and Ducharme MP: Metabolism and disposition of resveratrol in rats: Extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp Ther 302: 369-373, 2002.
69. Belguendouz L, Fremont L and Linard A: Resveratrol inhibits metal ion-dependent and independent peroxidation of porcine low-density lipoproteins. Biochem Pharmacol 53: 1347-1355, 1997.
70. Jannin B, Menzel M, Berlot JP, Delmas D, Lancon A and Latruffe N: Transport of resveratrol, a cancer chemopreventive agent, to cellular targets: Plasmatic protein binding and cell uptake. Biochem Pharmacol 68: 1113-1118, 2004.
71. Lançon A, Delmas D, Osman H, Thénot JP, Jannin B and Latruffe N: Human hepatic cell uptake of resveratrol: Involvement of both passive diffusion and carrier-mediated process. Biochem Biophys Res Commun 316: 1132-1137, 2004.
72. Lucas R, Alcantara D and Morales JC: A concise synthesis of glucuronide metabolites of urolithin-B, resveratrol, and hydroxytyrosol. Carbohydr Res 344: 1340-1346, 2009.
73. Bertelli AA, Giovannini L, Stradi R, Bertelli A and Tillement JP: Plasma, urine and tissue levels of trans-and cis-resveratrol (3,4’,5-trihydroxystilbene) after short-term or prolonged administration of red wine to rats. Int J Tissue React 18: 67-71, 1996.
74. El Mohsen MA, Marks J, Kuhnle G, Moore K, Debnam E, Kaila Srai S, Rice-Evans C and Spencer JP: Absorption, tissue distribution and excretion of pelargonidin and its metabolites following oral administration to rats. Br J Nutr 95: 51-58, 2006.
75. Vitrac X, Desmoulière A, Brouillaud B, Krisa S, Deffieux G, Barthe N, Rosenbaum J and Mérillon JM: Distribution of [14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. Life Sci 72: 2219-2233, 2003.
76. De Santi C, Pietrabissa A, Spisni R, Mosca F and Pacifici GM: Sulphation of resveratrol, a natural product present in grapes and wine, in the human liver and duodenum. Xenobiotica 30: 609-617, 2000.
77. Koga CC, Andrade JE, Ferruzzi MG and Lee Y: Stability of trans-resveratrol encapsulated in a protein matrix produced using spray drying to UV light stress and simulated gastro-intestinal digestion. J Food Sci 81: C292-C300, 2016.
78. Teskac K and Kristl J: The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol. Int J Pharm 390: 61-69, 2010.
79. Nam JB, Ryu JH, Kim JW, Chang IS and Suh KD: Stabilization of resveratrol immobilized in monodisperse cyano-functionalized porous polymeric microspheres. Polymer 46: 8956-8963, 2005.
80. Shi G, Rao L, Yu H, Xiang H, Yang H and Ji R: Stabilization and encapsulation of photosensitive resveratrol within yeast cell. Int J Pharm 349: 83-93, 2008.
81. Kesisoglou F, Panmai S and Wu Y: Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev 59: 631-644, 2007.
82. Rasenack N and Müller BW: Crystal habit and tableting behavior. Int J Pharm 244: 45-57, 2002.
83. Juan ME, Vinardell MP and Planas JM: The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful. J Nutr 132: 257-260, 2002.
84. Leonard SS, Xia C, Jiang BH, Stinefelt B, Klandorf H, Harris GK and Shi X: Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem Biophys Res Commun 309: 1017-1026, 2003.
85. Halliwell B and Gutteridge JM: Role of free radicals and catalytic metal ions in human disease: An overview. Methods Enzymol 186: 1-85, 1990.
86. Rizvi SI and Pandey KB: Activation of the erythrocyte plasma membrane redox system by resveratrol: A possible mechanism for antioxidant properties. Pharmacol Rep 62: 726-732, 2010.
87. Das S and Das DK: Anti-inflammatory responses of resveratrol. Inflamm Allergy Drug Targets 6: 168-173, 2007.
88. Birben E, Sahiner UM, Sackesen C, Erzurum S and Kalayci O: Oxidative stress and antioxidant defense. World Allergy Organ J 5: 9-19, 2012.
89. Simon HU, Haj Yehia A and Levi Schaffer F: Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis 5: 415-418, 2000.
90. Kim CH, Jeon HM, Lee SY, Jeong EK, Ju MK, Park BJ, Park HG, Lim SC, Han SI and Kang HS: Role of reactive oxygen species-dependent protein aggregation in metabolic stress-induced necrosis. Int J Oncol 37: 97-102, 2010.
91. la Lastra CA and Villegas I: Resveratrol as an antioxidant and pro-oxidant agent: Mechanisms and clinical implications. Biochem Soc Trans 35: 1156-1160, 2007.
92. Azmi AS, Bhat SH, Hanif S and Hadi SM: Plant polyphenols mobilize endogenous copper in human peripheral lymphocytes leading to oxidative DNA breakage: A putative mechanism for anticancer properties. FEBS Lett 580: 533-538, 2006.
93. Jang M and Pezzuto JM: Cancer chemopreventive activity of resveratrol. Drugs Exp Clin Res 25: 65-77, 1999.
94. Cao Z and Li Y: Potent induction of cellular antioxidants and phase 2 enzymes by resveratrol in cardiomyocytes: Protection against oxidative and electrophilic injury. Eur J Pharmacol 489: 39-48, 2004.
95. Yen GC, Duh PD and Lin CW: Effects of resveratrol and 4-hexylresorcinol on hydrogen peroxide-induced oxidative DNA damage in human lymphocytes. Free Radic Res 37: 509-514, 2003.
96. Melov S: Therapeutics against mitochondrial oxidative stress in animal models of aging. Ann N Y Acad Sci 959: 330-340, 2002.
97. Ates O, Cayli SR, Yucel N, Altinoz E, Kocak A, Durak MA, Turkoz Y and Yologlu S: Central nervous system protection by resveratrol in streptozotocin-induced diabetic rats. J Clin Neurosci 14: 256-260, 2007.
98. Belguendouz L, Frémont L and Gozzelino MT: Interaction of transresveratrol with plasma lipoproteins. Biochem Pharmacol 55: 811-816, 1998.
99. Rotondo S, Rajtar G, Manarini S, Celardo A, Rotillo D, de Gaetano G, Evangelista V and Cerletti C: Effect of trans-resveratrol, a natural polyphenolic compound, on human polymorphonuclear leukocyte function. Br J Pharmacol 123: 1691-1699, 1998.
100. West JD and Marnett LJ: Endogenous reactive intermediates as modulators of cell signaling and cell death. Chem Res Toxicol 19: 173-194, 2006.
101. Lee HS, Kim HN, Jung MH and Choi JY: Electrically evoked potentials recorded in a patient with auditory neuropathy. Cochlear Implants Int 5 (Suppl 1): S231, 2004.
102. Rizvi SI and Maurya PK: Alterations in antioxidant enzymes during aging in humans. Mol Biotechnol 37: 58-61, 2007.
103. Wenzel U, Nickel A and Daniel H: Increased mitochondrial palmitoylcarnitine/carnitine countertransport by flavone causes oxidative stress and apoptosis in colon cancer cells. Cell Mol Life Sci 62: 3100-3105, 2005.
104. Guo R, Su Y, Liu B, Li S, Zhou S and Xu Y: Resveratrol suppresses oxidised low-density lipoprotein-induced macrophage apoptosis through inhibition of intracellular reactive oxygen species generation, LOX-1, and the p38 MAPK pathway. Cell Physiol Biochem 34: 603-616, 2014.
105. Dani C, Bonatto D, Salvador M, Pereira MD, Henriques JA and Eleutherio E: Antioxidant protection of resveratrol and catechin in Saccharomyces cerevisiae. J Agric Food Chem 56: 4268-4272, 2008.
106. Dirks Naylor AJ: Cellular effects of resveratrol in skeletal muscle. Life Sci 84: 637-640, 2009.
107. Pandey KB and Rizvi SI: Protective effect of resveratrol on formation of membrane protein carbonyls and lipid peroxidation in erythrocytes subjected to oxidative stress. Appl Physiol Nutr Metab 34: 1093-1097, 2009.
108. Pandey KB and Rizvi SI: Plant polyphenols as dietary antioxidants in human health and disease. Oxid Med Cell Longev 2: 270-278, 2009.
109. Rizvi SI, Jha R and Pandey KB: Activation of erythrocyte plasma membrane redox system provides a useful method to evaluate antioxidant potential of plant polyphenols. Methods Mol Biol 594: 341-348, 2010.
110. Goldberg DM, Yan J and Soleas GJ: Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem 36: 79-87, 2003.
111. Perrone D, Ardito F, Giannatempo G, Dioguardi M, Troiano G, Lo Russo L, DE Lillo A, Laino L and Lo Muzio L: Biological and therapeutic activities, and anticancer properties of curcumin. Exp Ther Med 10: 1615-1623, 2015.
112. Maioli E, Torricelli C and Valacchi G: Rottlerin and cancer: Novel evidence and mechanisms. Scientific World Journal 2012: 350826, 2012.
113. Russo M, Russo GL, Daglia M, Kasi PD, Ravi S, Nabavi SF and Nabavi SM: Understanding genistein in cancer: The ‘good’ and the ‘bad’ effects: A review. Food Chem 196: 589-600, 2016.
114. Brito AF, Ribeiro M, Abrantes AM, Pires AS, Teixo RJ, Tralhão JG and Botelho MF: Quercetin in cancer treatment, alone or in combination with conventional therapeutics? Curr Med Chem 22: 3025-3039, 2015.
115. Zhao X and Zhang J: Mechanisms for quercetin in prevention of lung cancer cell growth and metastasis. Zhong Nan Da Xue Xue Bao Yi Xue Ban 40: 592-597, 2015 (In Chinese).
116. Feitelson MA, Arzumanyan A, Kulathinal RJ, Blain SW, Holcombe RF, Mahajna J, Marino M, Martinez Chantar ML, Nawroth R, Sanchez Garcia I, et al: Sustained proliferation in cancer: Mechanisms and novel therapeutic targets. Semin Cancer Biol 35 (Suppl): S25-S54, 2015.
117. Yu XD, Yang JL, Zhang WL and Liu DX: Resveratrol inhibits oral squamous cell carcinoma through induction of apoptosis and G2/M phase cell cycle arrest. Tumour Biol 37: 2871-2877, 2016.
118. Ray JG, Ranganathan K and Chattopadhyay A: Malignant transformation of oral submucous fibrosis: Overview of histopathological aspects. Oral Surg Oral Med Oral Pathol Oral Radiol 122: 200-209, 2016.
119. Sharma M and Radhakrishnan R: Limited mouth opening in oral submucous fibrosis: Reasons, ramifications, and remedies. J Oral Pathol Med: Oct 15, 2016 (Epub ahead of print).
120. Chang YC, Lin CW, Yu CC, Wang BY, Huang YH, Hsieh YC, Kuo YL and Chang WW: Resveratrol suppresses myofibroblast activity of human buccal mucosal fibroblasts through the epigenetic inhibition of ZEB1 expression. Oncotarget 7: 12137-12149, 2016.
121. Mohan A, Narayanan S, Balasubramanian G, Sethuraman S and Krishnan UM: Dual drug loaded nanoliposomal chemotherapy: A promising strategy for treatment of head and neck squamous cell carcinoma. Eur J Pharm Biopharm 99: 73-83, 2016.
122. ElAttar TM and Virji AS: Modulating effect of resveratrol and quercetin on oral cancer cell growth and proliferation. Anticancer Drugs 10: 187-193, 1999.
123. Lin FY, Hsieh YH, Yang SF, Chen CT, Tang CH, Chou MY, Chuang YT, Lin CW and Chen MK: Resveratrol suppresses TPA-induced matrix metalloproteinase-9 expression through the inhibition of MAPK pathways in oral cancer cells. J Oral Pathol Med 44: 699-706, 2015.
124. Masuelli L, Di Stefano E, Fantini M, Mattera R, Benvenuto M, Marzocchella L, Sacchetti P, Focaccetti C, Bernardini R, Tresoldi I, et al: Resveratrol potentiates the in vitro and in vivo anti-tumoral effects of curcumin in head and neck carcinomas. Oncotarget 5: 10745-10762, 2014.
125. Shan Z, Yang G, Xiang W, Pei Jun W and Bin Z: Effects of resveratrol on oral squamous cell carcinoma (OSCC) cells in vitro. J Cancer Res Clin Oncol 140: 371-374, 2014.